enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Breakthrough Gene Editing Technique Offers Hope for Stargardt ...

   lite.aol.com/tech/story/0022/20250108/1001042169.htm

   Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration. This groundbreaking study, published in Nature Medicine on 8 January 2025, demonstrates the therapeutic use of a precision gene editing technology called base editing.

3. Gildeuretinol - Wikipedia

   en.wikipedia.org/wiki/Gildeuretinol

   Gildeuretinol is an investigational new drug being developed by Alkeus Pharmaceuticals for the treatment of retinal diseases, particularly Stargardt disease and geographic atrophy secondary to age-related macular degeneration (AMD).

4. Gene therapy of the human retina - Wikipedia

   en.wikipedia.org/wiki/Gene_therapy_of_the_human...

   Following the successful clinical trials in LCA, researchers have been developing similar treatments using adeno-associated virus for age-related macular degeneration (AMD). To date, efforts have focused on long-term delivery of VEGF inhibitors to treat the wet form of macular degeneration. Whereas wet AMD is currently treated using frequent ...

5. EyePoint Pharmaceuticals Announces First Patient Dosed in ...

   lite.aol.com/tech/story/0022/20241024/9261009.htm

   WATERTOWN, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the first patient has been dosed in the Phase 3 LUGANO clinical trial of DURAVYU ...

6. List of drugs granted breakthrough therapy designation

   en.wikipedia.org/wiki/List_of_drugs_granted...

   To treat geographic atrophy secondary to age-related macular degeneration [4] Cipaglucosidase alfa: To treat late-onset Pompe disease with miglustat [4] Dabrafenib: Dostarlimab: Eflornithine: Elranatamab: To treat relapsed or refractory multiple myeloma after at least four lines of therapy [4] Enfortumab vedotin: Iptacopan

7. FDA Approves Biosimilars for Macular Degeneration Treatment - AOL

   www.aol.com/fda-approves-biosimilars-macular...

   Macular degeneration treatment is safe and effective. The FDA approval was based on a review of scientific evidence showing that both drugs are “highly similar” to Regeneron Pharmaceuticals’ ...